LNG ENERGY GROUP CORP by LNG ENERGY GROUP CORP Stock (OTC: LNGNF)

LNG ENERGY GROUP CORP by LNG ENERGY GROUP CORP (OTC:LNGNF) Stock, Quote.Headers.trade-ideas

LNG ENERGY GROUP CORP by LNG ENERGY GROUP CORP

Benchmark analyst Cody Acree reiterates Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and raises the price target from $115 to $135.

News

Price Target

Reiteration

Analyst Ratings

MRVL

Benchmark Reiterates Buy on Marvell Tech, Raises Price Target to $135

TLRY

Hop Valley Brewing And Subsidiary Of Tilray Brands, Is Excited To Announce Its New Partnership With The Portland Trail Blazers And The Opening Of The Hop Valley Brewing Hop Box Bar Inside Moda Center

Keybanc analyst Sophie Karp downgrades DTE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTE#NYSE">DTE</a>) from Overweight to Sector Weight.

Downgrades

Keybanc Downgrades DTE Energy to Sector Weight

Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.08 by 150 percent. The company reported quarterly sales of $2.88 billion which missed the analyst consensus estimate of $2.90 billion by 0.88 percent. This is a 5.02 percent increase over sales of $2.74 billion the same period last year.

Earnings

CHWY

Chewy Q3 2024 Adj EPS $0.20 Beats $0.08 Estimate, Sales $2.88B Miss $2.90B Estimate

D. Boral Capital analyst Jason Kolbert initiates coverage on Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) with a Buy rating and announces Price Target of $15.

Initiation

COYA

D. Boral Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $15

Contracts

AIRI

Air Industries announced that it has secured a follow-on contract valued at approximately $4.0M for arresting gear components to be used on the F-35 Lightning II fighter aircraft

Needham analyst Quinn Bolton maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and raises the price target from $95 to $120.

Needham Maintains Buy on Marvell Tech, Raises Price Target to $120

MGRX

Mangoceutical Announced That It Has Launched An Investigation Into Potential Stock Manipulation Related To And Following Its Recent Reverse Stock Split, Which Was Effective As Of October 16, 2024

The trial sites include esteemed institutions across the Northeast of the United States.
Additional trial sites include:
<ul>
<li>Yale University</li>
<li>Johns Hopkins University</li>
<li>Cornell University</li>
<li>University at Buffalo (SUNY)</li>
<li>University of Massachusetts (UMass)</li>
<li>Thomas Jefferson University</li>
</ul>

TLSA

Tiziana Life Sciences Broadens Phase 2 Clinical Trial For Non-Active Secondary Progressive Multiple Sclerosis To Additional U.S. Medical Institutions

Management

STGW

Stagwell Announced The Appointment Of George Brady As CEO

Can-Fite BioPharma Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANF#NYSE">CANF</a>) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announced today that a patient currently treated with Namodenoson in a compassionate use program in Can-Fite's&nbsp; Phase II Liver Cancer Study has an overall survival time of 8 years with a complete response.
The patient, who suffered from advanced liver cancer was enrolled in the former Can-Fite Phase II study, &nbsp;continue to be treated with Namodenoson, and has now an overall survival of 8 years, with &nbsp;disappearance of ascites, normal liver function, good quality of life and is defined as a long term complete response.
Can-Fite is currently enrolling patients in Israel, Europe and the US for a pivotal Phase III clinical study for patients with advanced HCC as a 2nd or 3rd line treatment and Namodenoson is administered twice daily orally. &nbsp;The study protocol has been agreed upon with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).
Namodenoson has Orphan Drug status with both the FDA and EMA, as well as Fast Track Status with the FDA for the treatment of HCC. A compassionate use program has been ongoing in Israel and Romania.

CANF

Can-Fite BioPharma Announced 8 Years Survival For Advanced Liver Cancer Patient Treated With Can-Fite's Namodenoson Drug

EYPT

EyePoint Pharmaceuticals Announced That The First Patient Has Been Dosed In The LUCIA Trial, The Company's Second Global Phase 3 Clinical Trial Of DURAVYU, Formerly EYP-1901, For The Treatment Of Wet Age-related Macular Degeneration

Needham analyst Mike Cikos maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Buy and raises the price target from $100 to $115.

OKTA

Needham Maintains Buy on Okta, Raises Price Target to $115

UBS analyst Jonathan Yong initiates coverage on eHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHTH#NASDAQ">EHTH</a>) with a Neutral rating and announces Price Target of $5.5.

EHTH

UBS Initiates Coverage On eHealth with Neutral Rating, Announces Price Target of $5.5

BOOM

DMC Global Announced It Inked A Deal With Its Arcadia Products Joint Venture Partners That Establishes September 6, 2026, As The Earliest Date DMC Can Be Required To Purchase The Remaining 40% Of Arcadia Under The Put Option Contained In Arcadia's Operating Agreement

HC Wainwright &amp; Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) with a Buy and raises the price target from $64 to $72.

RVMD

HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $72

As a result of the proposed transaction with Sophos, Secureworks is suspending financial guidance for the fourth quarter and fiscal year 2025. As previously announced, Secureworks will not hold an earnings conference call for the third quarter of fiscal year 2025.

Guidance

SCWX

SecureWorks Suspends Financial Guidance For Q4 and FY25 Due To Proposed Transaction With Sophos

STOK

Stoke Therapeutics Announced That It Has Received Breakthrough Therapy Designation From The US Food And Drug Administration For Zorevunersen For The Treatment Of Dravet Syndrome With A Confirmed Mutation, Not Associated With Gain-of-function, In The SCN1A Gene

Needham analyst Mike Cikos maintains Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) with a Buy and maintains $22 price target.

BASE

Needham Maintains Buy on Couchbase, Maintains $22 Price Target

AVIR

Atea Pharmaceuticals Announced That The Company's Phase 2 Study Of The Regimen Of Bemnifosbuvir, A Nucleotide Analog Polymerase Inhibitor, And Ruzasvir, An Ns5a Inhibitor, For Treatment Of Hepatitis C Virus Met Its Primary Endpoints Of Safety And Sustained Virologic Response At 12 Weeks Post-treatment

LNG Energy Group (TSE:LNGE) has released an update. LNG Energy Group has successfully concluded its annual general and special meeting, with shareh...

LNG Energy Group Shareholders Show Strong Support

LNG Energy Group (TSE:LNGE) has released an update. LNG Energy Group welcomes David Lawler, former Chairman and President of BP America and a seaso...

LNG Energy Group Appoints Industry Veteran to Board

LNG Energy Group (TSE:LNGE) has released an update. LNG Energy Group has announced initiatives aimed at aligning the interests of its shareholders,...

LNG Energy Group Unveils Shareholder Alignment Measures

LNG Energy Group (TSE:LNGE) has released an update. LNG Energy Group, a natural resources company focused on Latin American oil and gas assets, has...

LNG Energy Group Set for Virtual Investor Conference

LNG Energy Group (TSE:LNGE) has released an update. LNG Energy Group has announced the establishment of a new Oilfield Services Division within its...

LNG Energy Group Unveils New Oilfield Services Division

LNG Energy Group (TSE:LNGE) has released an update. LNG Energy Group reported a second quarter with solid financials, including an Adjusted EBITDAX...

LNG Energy Group Expands Amid Solid Q2 Financials

LNG Energy reports Q2 results

LNG Energy provides operational update of its Colombian operations; appoints interim COO

LNG Energy Group (TSE:LNGE) has released an update. LNG Energy Group has released an interim reserves evaluation of its assets in Venezuela, reveal...

LNG Energy Group Announces Venezuelan Reserves Valuation

As previously disclosed on October 21, 2024 and November 20, 2024, as a result of unexpected production restrictions at certain wells in the Buller...

Comments

LNG ENERGY GROUP CORP by LNG ENERGY GROUP CORP

LNG ENERGY GROUP CORP by LNG ENERGY GROUP CORP (LNGNF) Forecast

LNG ENERGY GROUP CORP by LNG ENERGY GROUP CORP (OTC:LNGNF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga